4-((5-methoxy-1H-benzo[d]imidazol-2-yl)methylamino)benzimidamide

ID: ALA4549483

PubChem CID: 155550727

Max Phase: Preclinical

Molecular Formula: C16H17N5O

Molecular Weight: 295.35

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  COc1ccc2[nH]c(CNc3ccc(C(=N)N)cc3)nc2c1

Standard InChI:  InChI=1S/C16H17N5O/c1-22-12-6-7-13-14(8-12)21-15(20-13)9-19-11-4-2-10(3-5-11)16(17)18/h2-8,19H,9H2,1H3,(H3,17,18)(H,20,21)

Standard InChI Key:  RZADLVZIZRFESU-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 22 24  0  0  0  0  0  0  0  0999 V2000
   21.3840   -1.8026    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.0243   -1.8089    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.6117   -1.0948    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.7934   -1.0955    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.6111   -2.5187    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.7943   -2.5127    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.5361   -3.2878    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.1935   -3.7729    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.8578   -3.2975    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.1874   -4.6000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.9007   -5.0187    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.8947   -5.8458    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.1752   -6.2525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.1688   -7.0788    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.8826   -7.4984    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6043   -7.0857    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6071   -6.2607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.8777   -8.3256    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.1589   -8.7348    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.5915   -8.7434    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.0249   -0.3783    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   23.8520   -0.3778    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  6  2  0
  5  2  2  0
  2  3  1  0
  3  4  2  0
  4  1  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9  5  1  0
  8 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 12  1  0
 15 18  1  0
 18 19  2  0
 18 20  1  0
  3 21  1  0
 21 22  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4549483

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 295.35

Molecular Weight (Monoisotopic): 295.1433

AlogP: 2.47

#Rotatable Bonds: 5

Polar Surface Area: 99.81

Molecular Species: BASE

HBA: 4

HBD: 4

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 5

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 11.73

CX Basic pKa: 12.60

CX LogP: 0.33

CX LogD: -1.13

Aromatic Rings: 3

Heavy Atoms: 22

QED Weighted: 0.43

Np Likeness Score: -1.21

References

1. Walker AL, Bingham RP, Edgar EV, Ferrie A, Holmes DS, Liddle J, Polyakova O, Rella M, Smith KJ, Thorpe JH, Wang Y, White GV, Young RJ, Hovnanian A..  (2019)  Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.,  29  (12): [PMID:31005442] [10.1016/j.bmcl.2019.04.022]

Source

Source(1):

• Scientific Literature